The Board of Directors of the Company at their Meeting held on today i.e., Friday, November 14, 2025, have inter-alia considered and approved the Unaudited Financial Results / Statements ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts less than Nifty Microcap 250 and 4.5 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved unaudited Q2 and H1 FY26 results on November 14, 2025, along with a clean (unqualified) Limited Review Report from M/s S P A R K & Associates. Q2 FY26 revenue from operations grew about 20% year-on-year to Rs 12.09 crore (vs Rs 10.06 crore in Q2 FY25), while H1 FY26 revenue rose roughly 8% to Rs 20.52 crore. Q2 swung back to a small profit of Rs 3.93 lakh versus a loss of Rs 24.17 lakh a year ago, though H1 FY26 still ended with a net loss of Rs 9.92 lakh (improved from a Rs 19.53 lakh loss in H1 FY25). The balance sheet remains stressed: other equity is negative at minus Rs 1.01 crore, total borrowings of about Rs 22.02 crore sit against thin total equity of Rs 3.81 crore (debt/equity around 5.8x), and cash and cash equivalents are negligible at just Rs 0.62 lakh. The company operates in a single segment – manufacturing of gelatine and related by-products.
Revenue growth is a positive sign for a turnaround story, but persistent half-yearly losses, negative other equity, and very high leverage mean profitability recovery is still fragile and balance sheet risk remains. The stock may react cautiously until margin improvement translates into sustained profits.